Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M243,005Revenue $M53,634Net Margin (%)18.5Z-Score4.2
Enterprise Value $M249,753EPS $4.1Operating Margin %21.4F-Score6
P/E(ttm))25.5Cash Flow Per Share $0Pre-tax Margin (%)23.6Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %0Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %-0.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %14.2ROA % (ttm)8.1Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)14.3Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,399ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSJohn Hussman 2014-12-31 Reduce-0.4%$85.02 - $96.65
($92.49)
$ 101.319%Reduce -23.36%164,000
NVSLee Ainslie 2014-12-31 Add0.36%$85.02 - $96.65
($92.56)
$ 101.319%Add 90.55%519,369
NVSLee Ainslie 2014-09-30 Buy 0.38%$85.25 - $94.8
($90.27)
$ 101.3111%New holding272,570
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 101.3111%Reduce -98.51%9,646
NVSPRIMECAP Management 2014-09-30 Reduce-0.16%$85.25 - $94.8
($90.27)
$ 101.3111%Reduce -6.74%22,239,448
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 101.3113%Reduce -71.80%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 101.3113%Sold Out0
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 101.3113%Add 10.04%51,102,219
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 101.3120%Reduce -10.13%24,014,586
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 101.3120%Add 31.52%351,580
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 101.3123%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 101.3127%Sold Out0
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 101.3128%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 101.3128%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 101.3128%Add 39.50%741,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 101.3133%Reduce -85.39%726,200
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 101.3133%New holding531,689
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 101.3133%Reduce -21.03%33,456
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 101.3139%Add 2.65%48,438,459
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 101.3142%New holding5,086,362
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15563.73view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
      AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
      Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
      Novartis Goes A Step Forward In Treating Lung Cancer Mar 02 2015 
      Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
      Can These Three BioTech Companies Make It Big? Feb 20 2015 
      Pfizer Takes A Giant Leap In Treatment of Cancer Feb 12 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 

      More From Other Websites
      Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
      Science, patients driving rare disease drug research surge Mar 25 2015
      Science, patients driving rare disease drug research surge Mar 25 2015
      Johnson & Johnson May See EPS Drag Through 2018 Mar 24 2015
      Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog Mar 23 2015
      11 Promising New Drugs Expected to Make Billions in Sales Mar 23 2015
      Eminence Capital Downs Position in Valeant Pharmaceuticals Mar 23 2015
      Rationale for the Pharmacyclics–AbbVie Merger Mar 23 2015
      Week in Review: Big deals, lawsuits and bankruptcies dominate the news Mar 22 2015
      Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in... Mar 21 2015
      ​Judge rejects Amgen bid to stop biosimilar drug Mar 20 2015
      New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI... Mar 20 2015
      Amgen Loses Bid to Block a Biosimilar Version of its Best-Selling Drug Mar 20 2015
      Fast-growing Triad technology firm makes acquisition, receives $20M infusion of capital Mar 19 2015
      Judge Denies Amgen's Request to Block Novartis's Biosimilar of Neupogen Mar 19 2015
      5 Breakout Stocks to Trade for Gains After the Fed's Bombshell Mar 19 2015
      Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog Mar 18 2015
      To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher Mar 18 2015
      Novartis Division is Charged with Sex Discrimination by Former Employees Mar 18 2015
      Pharmalot.. Pharmalittle: We're Catching Up On Novartis, Actavis and Lots More!! Mar 18 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK